Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycythemia Vera 5Thrombocythemia, Essential 3Primary Myelofibrosis 3Myeloproliferative Disorders 2Hodgkin Disease 2Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × givinostat hydrochloride × Clear all
NCT00792506 2022-02-02

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Italfarmaco

Phase 2 Terminated
1 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡